Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 5/20 | 0.59 |
| ▸ | MME | P08473 | 4/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.57 |
| ▸ | CTSS | P25774 | 1/20 | 0.57 |
| ▸ | KLK8 | O60259 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | PLAT | P00750 | 1/20 | 0.52 |
| ▸ | KLK1 | P06870 | 1/20 | 0.52 |
| ▸ | KLK4 | Q9Y5K2 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.51 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.50 |
| ▸ | KYNU | Q16719 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | CETP | P11597 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7716999 | 0.99 | ECE1 (0.60) | ECE1MMECTSLCTSSKLK8 | |
| SCHEMBL10958149 | 0.90 | ECE1 (0.59) | ECE1MMECTSLCTSSKLK8 | |
| SCHEMBL15397886 | 0.85 | ACE2 (0.56) | ECE1MMEF2PLAUPLAT | |
| SCHEMBL10482881 | 0.84 | MME (0.56) | ECE1MMECTSLCTSSACE2 | |
| SCHEMBL10482873 | 0.84 | MME (0.56) | ECE1MMECTSLCTSSACE2 | |
| SCHEMBL10482879 | 0.84 | MME (0.56) | ECE1MMECTSLCTSSACE2 | |
| SCHEMBL1688341 | 0.83 | ECE1 (0.63) | ECE1MMECTSLCTSSF2 | |
| SCHEMBL11163834 | 0.82 | MME (0.55) | ECE1MMECTSLCTSSACE2 | |
| SCHEMBL10960586 | 0.82 | MME (0.52) | ECE1MMECTSLCTSSKLK8 | |
| SCHEMBL19021627 | 0.82 | CTSL (0.61) | ECE1MMECTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295082-B1 | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence | FDS PHARMA ASS (GB) | 2013-09-18 | — | — | EP | disclosed |
| EP-1394261-B1 | ANTIGENS FOR IMMUNISATION | FDS PHARMA ASS (GB) | 2011-03-30 | — | — | EP | disclosed |
| EP-2295082-A1 | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence | FDS Pharma Ass. (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-7560529-B2 | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence | FDS Pharma (GB) | 2009-07-14 | — | — | US | disclosed |
| WO-2008078177-A2 | METHOD FOR PRODUCING CATALYTIC ANTIBODIES (VARIANTS), ANTIGENS FOR IMMUNIZATION AND NUCLEOTIDE SEQUENCE | FDS PHARMA ASS. (RU) | 2008-07-03 | — | — | WO | disclosed |
| US-20070178109-A1 | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence | LIFEBIO LABORATORIES LLC | 2007-08-02 | — | — | US | disclosed |
| EP-1394261-A2 | METHOD FOR PRODUCING CATALYTIC ANTIBODIES (VARIANTS), ANTIGENS FOR IMMUNISATION AND NUCLEOTIDE SEQUENCE | ASGL - Farmatsevticjeskie Innovatsii, Zaptryote Aktsionernoe Obschestvo (RU) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070178109-A1 | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence | SSB, DNMT3L, NASP | ECE1 2134/4885MME 733/4885CTSL 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.